Kyntra Bio (KYNB) EBT (2014 - 2026)

Kyntra Bio has disclosed EBT across 13 years of filings, most recently posting $12.0 million for Q2 2026.

• In Q2 2026, EBT rose 186.92% year-over-year to $12.0 million; the TTM figure through Jun 2026 stood at -$30.9 million (up 64.66% YoY), while the FY2025 annual figure was -$58.3 million, up 61.99% from the prior year.
• EBT came in at $12.0 million for Q2 2026 at Kyntra Bio, up from -$15.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $12.0 million in Q2 2026 to a low of -$93.1 million in Q4 2023.
• Average EBT over 5 years is -$46.3 million, with a median of -$48.7 million recorded in 2024.
• Year-over-year, EBT plunged 285.51% in 2022 and surged 186.92% in 2026.
• Over 5 years, EBT stood at -$66.3 million in 2022, then sank by 40.36% to -$93.1 million in 2023, then jumped by 90.7% to -$8.7 million in 2024, then slumped by 68.65% to -$14.6 million in 2025, then soared by 181.95% to $12.0 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $12.0 million in Q2 2026, -$15.1 million in Q1 2026, and -$14.6 million in Q4 2025.